Priority Date: 27.06.12 (US 201213534560)

CTLA4 FUSION PROTEINS FOR THE TREATMENT OF DIABETES

  • Application ID: EP13810575
  • Status: EXAMINATION IN PROGRESS

Attorney

operating since 1920
1179.79
Headquarter in London and 4 offices
active in Legal Services, IP Consulting, and IP Portfolio Processing

Specialization

This patent has the IPC combination A61 (MEDICAL OR VETERINARY SCIENCE; HYGIENE) and C07 (ORGANIC CHEMISTRY) is specialized in the combination A61 and C07. We found, that TransMIT GmbH, Kailuweit & Uhlemann, Lederer Keller Patentanwälte Partnerschaft mbB, Vossius & Partner Patentanwälte Rechtsanwälte mbB, df-mp Dörries Frank-Molnia & Pohlman, Patentanwälte Rechtsanwälte PartG mbB and 191 others are specialized in all of these IPC classes. For a similar patent, they might be a good choice.

Timeline

  • 27.06.2012 - Priority Date (US 201213534560)
  • 03.01.2014 - Publication A1 (WO2014004857)
  • 06.05.2015 - Publication A1 (EP2866823)